Karyopharm Therapeutics Inc. Tech Stack

Commercial-stage oncology company focused on XPO1 inhibitor therapies

Pharmaceutical Manufacturing Newton, MA 201–500 employees Public Company

Karyopharm is a public pharmaceutical company developing XPO1-targeted cancer drugs across multiple indications. The tech stack leans heavily on Veeva (vault and broader suite) alongside standard enterprise tools—typical for regulated biotech—but the hiring profile is heavily weighted toward interns (11 of 20 open roles) paired with director-level positions, suggesting simultaneous scaling of entry-level execution and leadership structure. Active projects center on first-in-class combination launch, clinical supply chain, and regulatory readiness, while pain points cluster around disease awareness, operational efficiency, and cross-functional coordination.

Tech Stack 17 technologies

Core StackZoom Power BI Smartsheet Power Query Word Excel PowerPoint EndNote Zotero Teams JMP SharePoint Veeva Vault Veeva

What Karyopharm Therapeutics Inc. Is Building

◆Challenges

Launching first-in-class combination therapy
Raising disease state awareness
Improving finance process efficiency
Streamlining financial operations
Inaccurate drug development process materials
Low intranet site usage
Poor content quality
Training program improvements
Cross-functional coordination challenges
Audit readiness activities

▲Active Projects

Manuscript preparation and submission
Development of tmf sops
Treatment landscape research
Clinical supply chain initiatives
Label development process
Annual quality management review of xpovio products
First-in-class combination launch
Disease state awareness and market education
Regulatory document review
Research ai tools for finance processes

Hiring Activity

Decelerating20 roles · 4 in 30d

Department

Healthcare

Ops

Research

Quality

Data

Finance

Legal

Seniority

Intern

Director

Senior

Mid

Notable leadership hires: Business Director

Company intelligence

Find more companies like Karyopharm Therapeutics Inc. by tech stack, pain points and active projects

Get started free

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics is a public commercial-stage pharmaceutical company headquartered in Newton, MA, with 201–500 employees. The company develops novel cancer therapies targeting XPO1 inhibition across multiple indications: multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). Operations span clinical research, drug development, regulatory affairs, and commercial functions. Current work includes manuscript preparation, clinical trial conduct, treatment landscape research, regulatory submissions, and quality assurance of approved products. The organization is actively hiring across healthcare, operations, research, and quality functions in the US and UK.

HeadquartersNewton, MA

Company Size201–500 employees

Hiring MarketsUnited States, United Kingdom

Frequently Asked Questions

What is Karyopharm's drug development focus?

Karyopharm develops XPO1 inhibitor therapies for multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). Current priorities include a first-in-class combination launch and quality assurance of Xpovio products.

What software does Karyopharm use for drug development?

Karyopharm uses Veeva Vault and the broader Veeva suite for regulatory compliance and document management, supplemented by JMP for statistical analysis, Zotero for reference management, and standard Microsoft Office and collaboration tools.

Where is Karyopharm Therapeutics headquartered?

Karyopharm is headquartered in Newton, MA. The company is actively hiring in the United States and United Kingdom across clinical, research, operations, and quality functions.